NCT02100670

Brief Summary

This Phase III pivotal efficacy study will assess efficacy and onset of pain relief of MFC51123 gel vs. placebo and MFC51123 gel vs. 1% diclofenac gel and 3% menthol gel in participants with an ankle sprain to support topical MFC51123 gel registration.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
385

participants targeted

Target at P75+ for phase_3 pain

Timeline
Completed

Started Nov 2013

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

March 27, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 1, 2014

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 22, 2015

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

January 12, 2018

Completed
Last Updated

January 12, 2018

Status Verified

May 1, 2017

Enrollment Period

1.3 years

First QC Date

March 27, 2014

Results QC Date

June 2, 2016

Last Update Submit

January 11, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel

    AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.

    up to 72 hours

Secondary Outcomes (13)

  • AUC1-3 Days of PI on Movement for Diclofenac Sodium + Methanol, Diclofenac, Methanol and Placebo

    up to 72 hours

  • Pain Intensity Difference (PID) on Movement

    Baseline to 10 days

  • PID at Rest

    Baseline to 10 days

  • Pain Relief Score (PRS)

    Day 1 to Day 7

  • Sum of Pain Intensity Difference (SPID)

    Baseline to Day 7

  • +8 more secondary outcomes

Study Arms (4)

1% diclofenac sodium plus 3% menthol

EXPERIMENTAL

1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.

Drug: 1% diclofenac sodium plus 3% menthol

1% diclofenac sodium plus 0.09% menthol

EXPERIMENTAL

1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.

Drug: 1% diclofenac sodium plus 0.09% menthol

3% menthol

EXPERIMENTAL

3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.

Drug: 3% menthol

Placebo with 0.09% menthol gel

PLACEBO COMPARATOR

Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.

Drug: Placebo with 0.09% menthol gel

Interventions

To be applied four times daily for 10 days.

1% diclofenac sodium plus 3% menthol

To be applied four times daily for 10 days.

1% diclofenac sodium plus 0.09% menthol

To be applied four times daily for 10 days.

3% menthol

To be applied four times daily for 10 days.

Placebo with 0.09% menthol gel

Eligibility Criteria

Age16 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 16-65 years
  • Good general and mental health
  • Grade I or Grade II acute sprain of the lateral ankle within 24 hours of Visit 1, a pain intensity score of the ankle sprain that is ≥ 5 as measured on an 11-point numerical rating scale, and a peri-malleolar edema (sub-malleolar perimeter difference of ≥ 20mm between injured and uninjured ankle
  • Females of child-bearing age practicing a reliable method of contraception

You may not qualify if:

  • Pregnant or breast-feeding females
  • If participant has treated the ankle sprain with treatment such as oral or other topical pain relief medications, massage or physical therapy since experiencing the ankle sprain
  • Acute or chronic pain disorders, which may confound the study pain evaluations
  • Participant has has injury to both ankles or to both medial and lateral ligaments of the same ankle
  • Known or suspected hypersensitivity, allergy, intolerance or contraindication to the use of any of the study medications
  • Participant has a medical history of renal or hepatic disease, a current active peptic ulcer or a history of upper gastrointestinal bleeding or perforation related to previous NSAID therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

PAREXEL International - Sites in Germany

Berlin, D-14050, Germany

Location

PAREXEL International, LLC

Berlin, D-14050, Germany

Location

pro scientia med im MARE Klinikum

Kiel, 24119, Germany

Location

Related Publications (1)

  • Lai PM, Collaku A, Reed K. Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial. J Int Med Res. 2017 Apr;45(2):647-661. doi: 10.1177/0300060517700322. Epub 2017 Mar 27.

MeSH Terms

Conditions

Pain

Interventions

DiclofenacMenthol

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenylacetatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsCyclohexanolsHexanolsFatty AlcoholsAlcoholsCyclohexane MonoterpenesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsMonoterpenesTerpenesLipids

Results Point of Contact

Title
GSK Response Center
Organization
GlaxoSmithKline

Study Officials

  • GSK Clinical Trials

    GlaxoSmithKline

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 27, 2014

First Posted

April 1, 2014

Study Start

November 1, 2013

Primary Completion

March 1, 2015

Study Completion

March 22, 2015

Last Updated

January 12, 2018

Results First Posted

January 12, 2018

Record last verified: 2017-05

Locations